Thiery-Vuillemin Antoine, Orillard Emeline, Mouillet Guillaume, Calcagno Fabien, Devillard Nadège, Bouchet Stéphane, Royer Bernard
Oncologie, CHU Besançon, 25030, Besançon cedex, France.
INSERM, UMR1098, 25020, Besançon cedex, France.
Cancer Chemother Pharmacol. 2017 Jun;79(6):1273-1276. doi: 10.1007/s00280-017-3320-y. Epub 2017 Apr 27.
Axitinib is approved with indication in patients with advanced renal cell carcinoma (RCC). Due to the localization of this cancer, physicians sometimes have to deal with hemodialyzed patients. Data exploring hemodialysis (HD) impact on axitinib pharmacokinetic (PK) or safety are lacking. To date, no data have been published on that problematic. This is the first publication discussing the assessment of axitinib PK for a patient undergoing HD. Our results suggest that there is no influence of HD on axitinib blood concentration. Interestingly, the membranes used are common and represent around 90% of the membranes used in routine for HD. Our data are also reassuring both from activity and from safety perspectives. In that case, axitinib administered at a dose of 6 mg twice a day was well tolerated and allowed 12 months of disease control. These results are in line with previous publications discussing other anti-angiogenic tyrosine kinase inhibitors pharmacokinetics, safety and activity among patients with metastatic RCC undergoing hemodialysis.
阿昔替尼已被批准用于晚期肾细胞癌（RCC）患者。由于这种癌症的位置，医生有时不得不处理接受血液透析的患者。目前缺乏关于血液透析（HD）对阿昔替尼药代动力学（PK）或安全性影响的数据。迄今为止，尚未有关于这个问题的相关数据发表。这是第一篇讨论对接受HD治疗的患者进行阿昔替尼PK评估的文章。我们的结果表明，HD对阿昔替尼血药浓度没有影响。有趣的是，所使用的透析膜是常见的，约占HD常规使用透析膜的90%。从活性和安全性角度来看，我们的数据也令人放心。在这种情况下，每天两次服用6毫克剂量的阿昔替尼耐受性良好，疾病得到了12个月的控制。这些结果与之前讨论转移性RCC血液透析患者中其他抗血管生成酪氨酸激酶抑制剂的药代动力学、安全性和活性的出版物一致。
